Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings

Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilus, Joseph C. Cappelleri, Claire Harrison

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: The goal of the research reported here was to understand the patient experience of living with myelofibrosis (MF) and establish content validity of the Modified Myeloproliferative Neoplasm Symptom Assessment Diary (MPN-SD). Methods: Qualitative interviews were performed in patients with MF, including both concept elicitation and cognitive debriefing. Patients with MF were asked to spontaneously report on their signs, symptoms, and impacts of MF, as well as their understanding of the MPN-SD content, and use of the tool on an electronic platform. A supplementary literature review and meetings with MF experts were also performed. Results: Twenty-three patients with MF participated in qualitative interviews. Signs and symptoms most commonly reported by ruxolitinib-experienced patients (n = 16) were: fatigue and/or tiredness (n = 16, 100%), shortness of breath (n = 11, 69%), pain below the ribs on the left side and/or stomach pain and/or abdominal pain (n = 9, 56%), and enlarged spleen (n = 9, 56%) and for ruxolitinib-naïve patients (n = 7) were: fatigue and/or tiredness (n = 6, 86%), pain below the ribs on the left side (n = 6, 86%), enlarged spleen (n = 4, 57%), full quickly/filling up quickly (n = 4, 57%), night sweats and/or general sweats (n = 4, 57%), and itching (n = 4, 57%). Patients demonstrated that they were able to read, understand, and provide meaningful responses to the MPN-SD. The final version of the MPN-SD includes the 10 most commonly reported concepts from the MF patient interviews. Conclusions: The findings demonstrate the comprehensiveness of the MPN-SD in assessing MF symptoms in both ruxolitinib-experienced and ruxolitinib-naïve patients, while remaining easy for patients to understand and complete.

Original languageEnglish (US)
Article number61
JournalHealth and Quality of Life Outcomes
Volume17
Issue number1
DOIs
StatePublished - Apr 11 2019

Keywords

  • Janus kinase inhibitors
  • Myeloproliferative disorders
  • Patient reported outcome measures
  • Primary myelofibrosis
  • Product labeling
  • Symptom assessment

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings'. Together they form a unique fingerprint.

  • Cite this

    Mesa, R. A., Su, Y., Woolfson, A., Prchal, J. T., Turnbull, K., Jabbour, E., Scherber, R., Shields, A. L., Krohe, M., Ojo, F., Pompilus, F., Cappelleri, J. C., & Harrison, C. (2019). Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings. Health and Quality of Life Outcomes, 17(1), [61]. https://doi.org/10.1186/s12955-019-1121-1